Keyword Analysis & Research: checkmate 649
Keyword Research: People who searched checkmate 649 also searched
Search Results related to checkmate 649 on Search Engine
-
First-line nivolumab plus chemotherapy versus chemotherapy ... - PubMed
https://pubmed.ncbi.nlm.nih.gov/34102137/
WEBJul 3, 2021 · First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398 (10294):27-40. doi: 10.1016/S0140-6736 (21)00797-2. Epub 2021 Jun 5.
DA: 57 PA: 22 MOZ Rank: 19
-
First-line nivolumab plus chemotherapy versus chemotherapy alone …
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/fulltext
WEBJun 5, 2021 · With nearly 1600 patients randomly assigned in the CheckMate 649 trial, nivolumab in combination with chemotherapy showed superior OS, along with PFS benefit, versus chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma.
DA: 29 PA: 8 MOZ Rank: 82
-
Expanded CheckMate-649 Data Confirm the Benefit of First-Line …
https://dailynews.ascopubs.org/do/expanded-checkmate-649-data-confirm-benefit-first-line-nivolumab-plus-chemotherapy
WEBJan 20, 2022 · CheckMate-649 is considered a landmark trial for gastrointestinal malignancies. “It is the first positive randomized trial in patients with advanced GC in the last 25 years of clinical research. It cleared the way to immunotherapy in these patients, and it will be a milestone in the treatment of advanced GC,” Dr. Cascinu explained.
DA: 86 PA: 88 MOZ Rank: 74
-
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric
https://ascopubs.org/doi/10.1200/JCO.23.01601
WEBFeb 21, 2024 · First-line nivolumab plus chemotherapy has been approved for the treatment of unresectable advanced, non–human epidermal growth factor receptor 2 (HER2)–positive gastric, gastroesophageal junction, and esophageal adenocarcinoma in over 50 countries on the basis of the results from CheckMate 649.
DA: 62 PA: 44 MOZ Rank: 42
-
Nivolumab plus chemotherapy or ipilimumab in gastro ... - Nature
https://www.nature.com/articles/s41586-022-04508-4
WEBMar 23, 2022 · Nature - Results in the CheckMate 649 phase 3 trial for first-line combined nivolumab and chemotherapy treatment continue to show clinically meaningful efficacy in gastric, gastro-oesophageal...
DA: 57 PA: 2 MOZ Rank: 59
-
FDA approves nivolumab in combination with chemotherapy for …
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal
WEBCHECKMATE-649 demonstrated a statistically significant improvement in PFS and OS for patients with PD-L1 CPS ≥5. Median OS was 14.4 months (95% CI: 13.1, 16.2) in the nivolumab plus...
DA: 43 PA: 94 MOZ Rank: 93
-
CheckMate 649: A randomized, multicenter, open-label, phase III …
https://ascopubs.org/doi/10.1200/JCO.2018.36.4_suppl.TPS192
WEBFeb 26, 2018 · CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer. | Journal of Clinical Oncology. Free access. Cancers of the Esophagus and …
DA: 59 PA: 45 MOZ Rank: 75
-
Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as …
https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.240
WEBJan 19, 2022 · Background: CheckMate 649 is a randomized, global phase 3 study of 1L programmed death-1 (PD-1) inhibitor–based therapies in advanced non-HER2-positive GC/GEJC/EAC that demonstrated superior overall survival (OS) with NIVO + chemo vs chemo, leading to approvals in the US and other countries.
DA: 5 PA: 68 MOZ Rank: 67
-
First-line nivolumab plus chemotherapy versus chemotherapy alone …
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/abstract
WEBJun 5, 2021 · First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial - The Lancet. Articles | Volume 398, ISSUE 10294, P27-40, July 03, 2021.
DA: 21 PA: 8 MOZ Rank: 42
-
Nivolumab plus chemotherapy versus chemotherapy as first …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436782/
WEBPMID: 34102137. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial.
DA: 77 PA: 96 MOZ Rank: 19
